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Purpose or Objective: To explore whether spatial dose 
measures explain the occurrence of rectal leakage, 
obstruction, and urgency after radiotherapy (RT) for localized 
prostate cancer. 
 
Material and Methods: Spatial dose measures were extracted 
for 210 patients treated with RT in 2005-2007, and who all 
completed patient-reported outcomes (PROs) at a median of 
3.6 years post-RT. The rectum was digitally unfolded and 2D 
maps were created for each patient by interpolating across 
25 points for 45º-sectors of each contour. The areas and 
extents (lateral and longitudinal) were calculated for dose 
thresholds between 35 and 75 Gy in 5 Gy steps over 9 equally 
distributed segments over the 2D maps (Fig. 1A), and their 
lateral and longitudinal combinations, resulting in a total of 
216 spatial dose metrics. Univariate (UVA) followed by 
multivariate (MVA) analysis using logistic regression with 50 
times iterated 5-fold cross-validation was applied to 
investigate the relationship between the spatial measures 
and ‘at least a moderate severity’ of five symptoms related 
to defecation urgency, fecal leakage, or obstruction. The 
prevalence for all investigated symptoms was ³ 25%. The UVA 
and MVA were first conducted in 70% of the data, and the 
performance of the most frequent MVA model, judged by the 
area under the receiver-operating characteristics curve 
(AUC), was investigated in the complete cohort. 
 
Results: On UVA 3-11 metrics (mean±SD: AUC=0.58±0.11) 
were suggested as potential predictors for the investigated 
symptoms (Table 1). The AUC of the final MVA models was 
0.57-0.62 (Fig. 1B). Defecation urgency was explained by 
metrics related to high doses (>55 Gy), fecal leakage was 
governed by medium to high-dose extensions in the anterior 
part of the rectum, and obstruction by metrics related to the 
lower part of the rectum, as well as extents of the high dose 
(>75 Gy).  
 
 
 
 
Conclusion: Our analysis suggests that spatial dose metrics 
explain symptoms of the gastrointestinal tract such as 
defecation urgency, fecal leakage and obstruction, and that 
these symptoms present spatial-specific relationships. The 
robustness of these results will be explored in other available 
cohorts (N>500) to evaluate whether these findings, and 
spatial dose metrics in general should be taken into account 
in the RT planning and treatment for localized prostate 
cancer. 
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Purpose or Objective: To investigate the relationship 
between patient-reported acute urinary (GU) toxicity (tox) 
and bladder local dose distribution in patients (pts) treated 
with radical RT for prostate cancer (PCa) by a pixel-wise 
method for analysis of bladder surface dose maps (DSMs). 
 
Material and Methods: Analyses were performed on the final 
cohort of pts of a multi-centric study, consisting of 539 pts 
with PCa treated with conventionally (CONV: 1.8 – 2Gy/fr) or 
moderately hypo-fractionated RT (HYPO: 2.2-2.7 Gy/fr) in 5 
fx/week. GU tox was evaluated by the International Prostate 
Symptoms Score (IPSS) given to the pts at the beginning and 
at the end of RT, comprising 7 questions relating to different 
symp: feeling of incomplete emptying (EMP), frequency 
(FRE), intermittency (INT), urgency (URG), weak stream 
(WST), straining (STR) and nocturia (NOC). We here 
considered the seven symp separately and moderate/severe 
tox for each item was selected as endpoint (score ≥4 at RT 
end), including only pts who had no disturbs before RT (IPSS 
at basal < 4). As different fractionation schemes were 
allowed, DSMs of all pts were corrected into 2Gy-equivalent 
maps using the LQ model, converting the dose in each pixel 
with an α/β equal to 10 Gy and a repair factor =0.7 Gy/day. 
DSMs of all pts were generated by unfolding the bladder: its 
contour was cut anteriorly at the points intersecting the 
sagittal plane passing through its centre of mass, normalised 
in the axial direction and aligned at the bladder base, at the 
posterior central point, generating a common frame for all 
pts. For each endpoint average DSMs of pts with/without tox 
were compared pixel by-pixel by two-sided t-tests, 
separately analyzing HYPO and CONV pts: the resulting p-
value maps were used for identifying the regions better 
discriminating between pts with/without tox, considering a 
threshold of p<0.01. 
 
Results: DSMs of 437/539 pts (81%) were available (185 CONV 
and 252 HYPO). EMP was reported by 28/358 (8%) pts, FRE by 
60/361 (17%), INT by 35/366 (10%), URG by 50/357 (14%), 
WST by 66/341 (19%), STR by 29/377 (8%) and NOC by 63/348 
(18%) pts. For HYPO pts, areas significantly correlated with 
GU tox were found for all endpoints (excepting WST) in the 
posterior region at 5-17 mm from the base of bladder, 
consistently with the bladder trigone, with evidence of a 
threshold effect around 85 Gy (2Gy equivalent). For CONV 
pts, only 2 endpoints (FRE and URG) showed significantly 
predictive areas, robustly summarized in the % surface 
receiving >50-70Gy at 5mm from the base and the vertical 
extension of 50-70Gy isodoses along the bladder central axis. 
In the figure, the results concerning FRE and URG are shown. 
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Conclusion: The method of DSMS analysis allowed to assess 
new local-dose descriptors that might be better correlated 
with tox and promises to find important applications in 
investigating urinary tox. The incorporation of the found local 
dose predictors into multi-variable models including clinical 
predictors is currently in progress. 
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Purpose or Objective: Current models for the prediction of 
xerostomia and sticky saliva after radiotherapy (RT) are 
based on clinical and dosimetric information. Our hypothesis 
is that such models can be improved by the addition of 
patient-specific characteristics, quantified in CT image 
biomarkers (IBMs). The aim of this study is to improve the 
performance of prediction models for patient-rated 
moderate-to-severe xerostomia (Xer12m) and sticky saliva 
(STIC12m) 12 months after radiotherapy with the addition of 
these IBMs obtained from CT images before the start of RT. 
 
Material and Methods: Head and neck cancer patients were 
primarily treated with RT alone or in combination with 
systemic treatment. The patient rated complications were 
prospectively collected (EORTC QLQ-H&N35).The potential 
CT IBMs represent geometric (20), CT intensity (24) and 
pattern characteristics (88) of the CT-image of the parotid 
(PG) and submandibular (SG) glands. Furthermore, 
Xerbaseline, tumour, patient characteristics and mean doses 
to contra- and ipsi-lateral PG and SG were 
considered.Variables were preselected by omitting the least 
prognostic variable if inter-variable correlation was larger 
than 0.80. Lasso regularisation was used to create 
multivariable logistic regression models with and without 
IBMs to predict patient rated moderate-to-severe Xer12m and 
Stic12m. A repeated 10-fold cross validation was used to 
determine the optimal regularization term lambda. The final 
models were internally validated by testing the models on 
bootstrapped data. 
 
Results: Of the 254 patients with follow-up information at 12 
months, 100 (39%) and 62 (24%) had moderate-severe 
xerostomia and sticky saliva, respectively. Pre-selection of 
variables resulted in a selection of 26 variables for XER12m 
and 28 variables for STIC12m. For xerostomia, the lasso 
regularization selected in addition to mean contra-lateral PG 
dose and Xerbaseline , the image biomarker “Short Run 
Emphasis” (SRE). This CT IBM quantifies the occurrence of 
short lengths of CT intensity repetitions and thereby 
indicates the homogeneity of the parotid tissue. For sticky 
saliva, the IBM maximum CT intensity of the submandibular 
gland was selected in addition to STICbaseline and mean dose 
to SGs. The maximum intensity of the SG was related with 
the intra-vascular contrast in the artery or vein supplying the 
SG.  
For the prediction of both Xer12m and STIC12m, the addition 
of the multivariable selected CT-IBMs improved the 
performance measures significantly compared to the models 
that were based on dose and baseline complaints only (table 
1). The models were stable when internally validated. 
 
 
 
Conclusion: Prediction of XER12m and STIC12m could be 
improved with CT derived IBMs. The IBM associated with 
XER12m, "short run emphasis", might be a measure of non 
functional fatty parotid tissue. The STIC12m IBM, maximum 
intensity was related with the submandibular vascularization. 
Both predictive IBMs might be independent measures of 
radiosensitivity of the PG and SG. 
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